Key statistics
On Friday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 10.63, -32.46% below its 52-week high of 15.74, set on Dec 08, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 10.82 |
|---|---|
| High | 11.17 |
| Low | 10.62 |
| Bid | 9.00 |
| Offer | 11.18 |
| Previous close | 10.86 |
| Average volume | 483.95k |
|---|---|
| Shares outstanding | 65.97m |
| Free float | 65.19m |
| P/E (TTM) | -- |
| Market cap | 701.26m USD |
| EPS (TTM) | -1.14 USD |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
- Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
More ▼
